PharmiNews

The Directory of Pharma Companies and News

Astellas

Astellas logo
Astellas Pharma EMEA operates in 40 countries across Europe, the Middle East and Africa, and is the EMEA regional business of Tokyo‐based Astellas Pharma Inc. Astellas is a pharmaceutical company dedicated to improving the health of people around the world through the provision of innovative and reliable pharmaceuticals. The organisation’s focus is to deliver outstanding R&D and marketing to continue growing in the world pharmaceutical market. Astellas’ presence in Europe also includes an R&D site and three manufacturing plants. The company employs over 4,500 people across the EMEA region. In 2013 Astellas was awarded SCRIP Pharmaceutical Company of the Year in recognition of its commercial success and pipeline development.
Category:
Category:

Astellas News

DateNews
2017-02-28Astellas and Affinivax Announce Worldwide Partnership for MAPS Vaccine targeting Pneumococcal Disease
2017-02-27Kyowa and Astellas enter into an Agreement for Exclusive Distribution and Promotion of Extended-Release Tablets of Queti...
2017-02-23Joint Storage and Transportation of Pharmaceuticals in Hokkaido by Astellas, Takeda, Teva Takeda Pharma and Teva Takeda ...
2017-02-08Astellas Announces Changes in Management Structure and Global Function (pdf 294KB)
2017-02-08Astellas Announces Personnel Changes and Organizational Changes (pdf 395KB)
2017-01-31Astellas Reports the First Nine Months Financial Results of FY2016 (pdf 434KB)
2017-01-31Astellas Executes License Agreement with Auration Biotech for the Development and Commercialization of AU-935
2017-01-31Astellas Announces Acquisition of Own Shares (pdf 190KB)
2017-01-30Astellas and Ironwood Report Positive Top-Line Results from Phase III Linaclotide Trial for Patients with Chronic Consti...
2017-01-18Astellas Announces Participation in Access Accelerated - Builds on Company Commitment to improve Access to Health -
2017-01-12Astellas Launches Second Phase of Global Campaign on CNN
2017-01-10Astellas Terminates Agreement with UMN Pharma for Cell Culture Based Influenza Vaccine Programs
2016-12-21Astellas Completes Acquisition of Ganymed Pharmaceuticals
2016-12-20AMGEN ASTELLAS AND ASTELLAS ANNOUNCE SUBMISSION OF APPLICATION FOR INVESTIGATIONAL OSTEOPOROSIS MEDICATION ROMOSOZUMAB I...
2016-12-20Astellas Announces FDA Fast Track Designation for ASP0892, DNA Vaccine for Mitigation of Severe Hypersensitivity Reactio...
2016-12-19Marketing Approval of LINZESS®, Treatment for Irritable Bowel Syndrome with Constipation in Japan - Provides a new thera...
2016-12-15Sysmex, Astellas and Daiichi Sankyo Sign Memorandum of Understanding on the Creation of a Method for Analyzing Circulati...
2016-12-15Pfizer and Astellas Announce Top-Line Results from Phase 4 PLATO Trial of XTANDI® (enzalutamide) Capsules in Patients wi...
2016-12-12Astellas Announces Transfer of Qutenza to Grünenthal
2016-12-08Astellas Research & Development Meeting Highlights?- Turning Innovative Science into Value for Patients -?pdf 237KB?
2016-12-07Astellas Launches Kiklin® Granules, a Treatment for Hyperphosphatemia, in Japan
2016-12-01Astellas Announces Status of Acquisition of Own Shares (pdf 196KB)
2016-11-30Initiatives to Pursue Operational Excellence
2016-11-18Antihypertensive Drug "Micatrio® Combination Tablets"
2016-11-09GUINNESS WORLD RECORDSTM Title Achieved for Organ Donor Registrations
2016-09-28Maruho and Astellas Enter License Agreement for the Development and Commercialization of a Topical Formulation of JAK In...
2016-09-28Astellas Receives Approval for Kiklin® Granules, a Treatment for Hyperphosphatemia, in Japan
2016-09-28Approval for Manufacturing and Marketing of "Micatrio® Combination Tablets," an Antihypertensive Drug -Japan's first ARB...
2016-09-20Vical and Astellas Announce Topline Results from a Phase 2 Study of Investigational Cytomegalovirus (CMV) Vaccine (ASP01...
2016-09-16Astellas Selected as a Dow Jones Sustainability Asia Pacific Index Component for Sixth Consecutive Year
2016-09-07Astellas donates ambulances on First Aid Day (September 9)
2016-08-22Astellas and World Transplant Games Federation Announce Launch of Fit for Life! to Promote Physical Activity in Transpla...
2016-08-09Astellas Submits New Drug Application for Extended-Release Tablets of Quetiapine Fumarate in Japan
2016-08-04Astellas Announces Transfer of U.S. Manufacturing Subsidiary to Avara (pdf 120KB)
2016-07-29Astellas Reports First Quarter Financial Results of FY2016 (pdf 164KB)
2016-07-29Astellas Launches DigiTx Partners, a Digital Health Investment Company in Partnership with MPM Capital
2016-07-28CYTOKINETICS AND ASTELLAS ANNOUNCE OPTION RIGHT FOR TIRASEMTIV AND EXPANSION OF GLOBAL COLLABORATION FOR CK-2127107 IN A...
2016-07-26Astellas and FibroGen Announce First Patient Treated in Phase 3 Studies and Positive Phase 2 Results of Roxadustat in Pa...
2016-07-06Astellas Named to FTSE4Good Sustainability Index for the Fifth Consecutive Year
2016-06-23The Institute of Medical Science, the University of Tokyo and Astellas Enter into a New Collaborative Development Agreem...
2016-06-03ASTELLAS AND MEDIVATION INITIATE PHASE III TRIAL OF ENZALUTAMIDE IN PATIENTS WITH TRIPLE-NEGATIVE BREAST CANCER
2016-05-31Astellas Announces Personnel Changes (pdf 48KB)
2016-05-25Thunderbolt Pharma, Inc., a Vitesse Biologics Company, Acquires Rights to BAFF/APRIL Dual Antagonist Program from Astell...
2016-05-23Astellas, Daiichi Sankyo, and Takeda Announce Research Collaboration on Establishing Biomarker Database on Healthy Adult...
2016-05-23THE RESULTS FROM A ONE YEAR TREATMENT OF REPATHA PRESENTED AT THE ANNUAL MEETING OF THE JAPAN DIABETES SOCIETY (JDS 2016...
2016-05-11Notice Regarding the Continuation of a Performance-linked Stock Compensation Scheme (pdf 197KB)
2016-05-11Astellas Announces Cancellation of Treasury Shares (pdf 75KB)
2016-04-27Astellas Announces Changes to Representative Director and Audit & Supervisory Board Member (pdf 54KB)
2016-04-27Astellas Co-sponsors C3 Prize
2016-04-21AMGEN ASTELLAS BIOPHARMA AND ASTELLAS INTRODUCE REPATHA® (EVOLOCUMAB) FOR THE TREATMENT OF HIGH CHOLESTEROL
2016-04-18Astellas Supports the 2016 Kumamoto Earthquake Relief Efforts
2016-04-08CHMP Issues Positive Opinion to Include New Data in European Label for XTANDI® (enzalutamide) (pdf 109KB)
2016-04-08Certain media coverage related to Astellas
2016-04-01Establishment and Start of Operations of Malaysia Subsidiary and Umbrella Organization Covering South East and South Asi...
2016-04-01Astellas Enters a New Collaborative Research Agreement with AIST to Discover Anti-protozoan Parasite Drugs for the Treat...
2016-04-01Astellas and LEO Pharma Close Transaction to Transfer Global Dermatology Business(pdf 95KB)
2016-03-29Astellas and Mitsubishi Tanabe Pharma Execute Agreement for Share of Compound Libraries
2016-03-25Pivotal Phase III Trial of enzalutamide Initiated in Metastatic Hormone Sensitive Prostate Cancer(pdf 111KB)
2016-03-22POSITIVE TOP-LINE RESULTS FROM PHASE 3 STUDY EVALUATING ROMOSOZUMAB IN MEN WITH OSTEOPOROSIS
2016-03-16Astellas Selected as a Nadeshiko Brand Component for Excellence in Providing Opportunities for Women(pdf 107KB)
2016-03-04Astellas Announces Personnel Changes (pdf 47KB)
2016-03-01Astellas Announces Management Structure Change (pdf 70KB)
2016-03-01Astellas Announces Personnel Changes and Organizational Change (pdf 47KB)
2016-03-01Status of Acquisition of Own Shares (pdf 92KB)
2016-03-01Astellas Announces Status of Acquisition of Own Shares (pdf 92KB)
2016-02-29Astellas Receives Approval for a Supplemental New Drug Application for Kiklin® Capsules, a Treatment for Hyperphosphatem...
2016-02-24Astellas Submits New Drug Application for Linaclotide, Treatment for Irritable Bowel Syndrome with Constipation, in Japa...
2016-02-23FDA Accepts For Review Supplemental New Drug Application for XTANDI® (enzalutamide) Capsules in Metastatic Castration-re...
2016-02-23POSITIVE TOP-LINE RESULTS FROM THE PHASE 3 STUDY OF ROMOSOZUMAB IN POSTMENOPAUSAL WOMEN WITH OSTEOPOROSIS (pdf 80KB)
2016-02-10Astellas Announces Results of Tender Offer to Acquire All Outstanding Shares of Ocata Therapeutics and Changes to Subsid...
2016-02-08Astellas Announces Personnel Changes and Organizational Changes (pdf 57KB)
2016-02-01Astellas and CLINO Announce License Agreement to Develop and Commercialize Gene Therapy to Treat Retinitis Pigmentosa
2016-01-29Astellas Announces Acquisition of Own Shares (pdf 139KB)
2016-01-22REPATHA® (EVOLOCUMAB) APPROVED AS FIRST PCSK9 INHIBITOR IN JAPAN FOR THE TREATMENT OF HIGH CHOLESTEROL(pdf 36KB)
2016-01-22Astellas Extends Tender Offer to Acquire All Outstanding Shares of Ocata Therapeutics - ASTELLAS IS COMMITTED TO TRANSAC...
2016-01-07Extension of agreement on Telmisartan (Micardis® family) (pdf 170KB)
2015-12-18Astellas Extends Tender Offer to Acquire All Outstanding Shares of Ocata Therapeutics
2015-12-11Bellicum and Astellas Announce License Agreement for Cancer Target PSCA in Cell and Gene Therapy
2015-12-09Presentation material for Press Conference on December 8
2015-12-02Notice of Completion of Acquisition of Own Shares (pdf 46KB)
2015-12-01Astellas and Ironwood Report Positive Top-Line Data from Phase III IBS-C Trial Conducted in Japan (pdf 505KB)
2015-12-01Astellas Announces Status of Acquisition of Own Shares (pdf 60KB)
2015-12-01Astellas Announces Personnel Change (pdf 46KB)
2015-11-20Astellas Commences Tender Offer to Acquire All Outstanding Shares of Ocata Therapeutics
2015-11-18Presentation for Astellas to Acquire Ocata Therapeutics
2015-11-13Named to 2015 Climate Disclosure Leadership Index -Recognized for perfect disclosure score for climate change informatio...
2015-11-11Astellas Transfers Its Global Dermatology Business to LEO Pharma (pdf 98KB)
2015-11-10Astellas to Acquire Ocata Therapeutics (pdf 44KB)
2015-11-10Presentation for Astellas to Acquire Ocata Therapeutics (pdf 1512KB)
2015-11-10The 2nd Year Results of C-OPERA, a Study of Anti-TNF-alpha Antibody Certolizumab Pegol,Announced at 2015 ACR/ARHP Annual...
2015-10-30Astellas Concludes Agreement with MicroBiopharm Japan on Transfer of Kiyosu Plant Business (pdf 49KB)
2015-10-30Astellas Announces Acquisition of Own Shares (pdf 64KB)
2015-10-29Astellas Initiates Phase 3 Registration Trial of gilteritinib (ASP2215) in Relapsed or Refractory Acute Myeloid Leukemia...
2015-10-09Astellas Pharma and Immunomic Therapeutics Announce Worldwide Partnership for LAMP-vax™ Products for Allergic Disease
2015-10-05Astellas Donates 6 Wheelchair Vans through the Flying Star Fund, an Employee-Led Social Contribution Fund
2015-09-30Submission of a Supplemental New Drug Application for ASP1585 Granule,a Treatment for Hyperphosphatemia, in Japan
2015-09-30Astellas and Chromocell Announce License and Collaboration Agreement to Develop and Commercialize New Therapies to Treat...
2015-09-18Astellas Selected as a Dow Jones Sustainability Asia Pacific Index Component for Fifth Consecutive Year
2015-09-17Astellas Supports Relief Efforts Following Typhoon in Eastern and Northern Japan
2015-09-08Astellas Named to FTSE4Good Sustainability Index
2015-09-07Astellas donates ambulances on First-Aid Day (September 9)
2015-08-27Notice of Completion of Acquisition of Own Shares (pdf 41KB)
2015-08-20Astellas Announces Changes in Personnel and Sales and Marketing Structure in Japan (pdf 56KB)
2015-07-31Astellas Establishes New Real World Informatics and Analytics Function
2015-07-30Astellas Provides Update on Phase 3 Study Evaluating Isavuconazole in Patients with Candidemia and Other Invasive Candid...
2015-07-23Astellas Initiates Collaborative Research with National Institute of Advanced Industrial Science and Technology by Utili...
2015-07-22"Cell therapy using human iPSC-derived renal progenitors ameliorates acute kidney injury in mice" published in "Stem Cel...
2015-07-16The Netherlands Decorates Masafumi Nogimori, Representative Director and Chairman of Astellas with "Officer in the Order...
2015-07-13Notice of Completion of Acquisition of Own Shares (pdf 201KB)
2015-06-15Results of Additional Analysis of Data from Japanese Clinical Trial of Anti-TNF-alpha Antibody Certolizumab Pegol Announ...
2015-06-02NEW ENZALUTAMIDE DATA IN TRIPLE-NEGATIVE BREAST CANCER PRESENTED AT THE 2015 AMERICAN SOCIETY OF CLINICAL ONCOLOGY ANNUA...
2015-06-02Astellas and Anokion to Collaborate on Immune Tolerance Therapeutics - Kanyos Bio established to develop products for Ce...
2015-06-01Astellas Announces Status of Acquisition of Own Shares (pdf 63KB)
2015-06-01ASTELLAS ANNOUNCES PRELIMINARY PHASE 1/2 SAFETY, TOLERABILITY AND EFFICACY DATA FOR ASP2215 IN PATIENTS WITH RELAPSED OR...
2015-05-27Presentation material of Strategic Plan 2015-2017
2015-05-26Astellas Announces Acquisition of Own Shares (pdf 62KB)
2015-05-26Announcement of Approval of Additional Indication for the TNF-? inhibitor Certolizumab Pegol (Generic Name) in Japan (pd...
2015-05-26Astellas Receives Approval for a Supplemental New Drug Application for Irribow®/Irribow® OD, a Treatment of Diarrhea-pre...
2015-05-26Astellas: Strategic Plan 2015-2017 (pdf 392KB)
2015-05-18ASTELLAS AND MEDIVATION ANNOUNCE NEW ENZALUTAMIDE DATA PRESENTED AT THE 2015 AMERICAN UROLOGICAL ASSOCIATION ANNUAL MEET...
2015-05-18MIRABEGRON AS ADD-ON TREATMENT TO SOLIFENACIN THERAPY DEMONSTRATED SUPERIOR RESULTS TO SOLIFENACIN MONOTHERAPY IN BESIDE...
2015-05-11Astellas Announces Cancellation of Treasury Shares (pdf 24KB)
2015-05-11Notice Regarding the Introduction of a Performance-linked Stock Compensation Scheme (pdf 76KB)
2015-05-08Astellas Supports Nepal Earthquake Relief Efforts
2015-04-24Astellas Announces Personnel Change (pdf 62KB)
2015-04-23Astellas Announces Consolidated Business Forecasts for Fiscal Year 2014 (pdf 45KB)
2015-04-23Astellas Nominates Director and Audit & Supervisory Board Member (pdf 41KB)
2015-04-23The Results of Japanese Clinical Trials of Anti-TNF-alpha Antibody Certolizumab Pegol were Announced at Leading Rheumato...
2015-04-22Astellas Pharma and Potenza Therapeutics Partner to Build a Portfolio of Immuno-oncology Therapeutics - Exclusive Collab...
2015-04-15MSD and Astellas sign a memorandum of understanding regarding co-development and co-commercialization of combination pro...
2015-04-03MD Anderson, Astellas Pharma Sign Option Agreement for Monoclonal Antibody Drug Targeting Acute Myeloid Leukemia
2015-04-03ENZALUTAMIDE DEMONSTRATES STATISTICALLY SIGNIFICANT IMPROVEMENT IN PROGRESSION FREE SURVIVAL COMPARED WITH BICALUTAMIDE ...
2015-04-01Astellas Celebrates 10th Anniversary
2015-03-25ASTELLAS AND MEDIVATION ANNOUNCE NEW ENZALUTAMIDE DATA PRESENTED DURING PLENARY PRESENTATIONS AT THE 2015 EUROPEAN ASSOC...
2015-03-20ANNOUNCEMENT OF MARKETING APPROVAL SUBMISSION?TO MHLW (JAPAN) FOR LDL CHOLESTEROL-LOWERING?MEDICATION EVOLOCUMAB
2015-03-17Astellas Submits Supplemental New Drug Application for Kiklin® Capsules, a Treatment for Hyperphosphatemia, in Japan
2015-03-16Notice of Completion of Acquisition of Own Shares
2015-03-09Astellas Receives FDA Approval for CRESEMBA® (isavuconazonium sulfate) for the Treatment of Invasive Aspergillosis and I...
2015-03-02Astellas Announces Status of Acquisition of Own Shares
2015-02-13Astellas Pharma Launches the Newest Element in its Global Corporate Brand Campaign On CNN's Global Broadcast Network (pd...
2015-02-05Enhancement of Astellas' Management Structure (pdf 82KB)
2015-02-05Astellas Announces Personnel Changes and Organization Changes (pdf 98KB)
2015-02-02Astellas Announces Acquisition of Own Shares
2015-02-02Graduate School of Medicine/Faculty of Medicine, Osaka University and Astellas establish joint research chair for R&D on...
2015-02-02ASTELLAS BROADENS COMMITMENT TO CLINICAL TRIAL DATA TRANSPARENCY
2015-01-30Astellas Pharma and Immunomic Therapeutics Announce Exclusive License for JRC2-LAMP-vax, a Vaccine for Japanese Red Ceda...
2015-01-23Astellas Announces FDA Anti-Infective Drugs Advisory Committee Recommends Approval of CRESEMBA® (isavuconazonium) for Tr...
2015-01-23ENZALUTAMIDE PHASE 2 TERRAIN TRIAL DEMONSTRATED STATISTICALLY SIGNIFICANT INCREASE IN PFS AS COMPARED TO BICALUTAMIDE IN...
2014-12-24CYTOKINETICS AND ASTELLAS ANNOUNCE EXPANSION OF COLLABORATION FOR DEVELOPMENT OF CK-2127107 IN SPINAL MUSCULAR ATROPHY A...
2014-12-15DATA PRESENTED FROM PHASE 2 STUDY OF ENZALUTAMIDE IN ADVANCED ANDROGEN-RECEPTOR POSITIVE, TRIPLE-NEGATIVE BREAST CANCER
2014-12-11Presentation material for Press Conference on December 10
2014-12-10DATA TO BE PRESENTED FROM PHASE 2 STUDY OF ENZALUTAMIDE IN ADVANCED ANDROGEN-RECEPTOR POSITIVE, TRIPLE-NEGATIVE BREAST C...
2014-12-09Astellas Named to FTSE4Good Sustainability Index for the Third Year
Brought to you by PharmiWeb.com - Latest Jobs in Pharma
Brought to you by www.pharmiweb.com - Latest Jobs in Pharma.